Abstract
It has long been assumed that there is a latent period of one to two weeks between beginning treatment with antidepressant drugs and evidence of clinical improvement (Oswald et al., 1972). However, there is an increasing feeling that this may be an over-simplification. Depression is a complex illness with many facets of which mood is only one. Overall rating scales may be a blunt instrument for detecting improvements in a multi-symptomatic state. There are hints in the literature that the response of certain symptoms to antidepressants may occur within a few days. There are also confounding factors: for example, some antidepressants, e.g. amitriptyline, are sedative and may improve sleep early, so altering responses as judged by rating scales.
This is a preview of subscription content, log in via an institution.
Preview
Unable to display preview. Download preview PDF.
References
Atterwill, C.R., and Tordoff, A.F.C. (1982). Effects of repeated lithium administration on the subcellular distribution of 5-hydroxytryptamine in rat brain. Br. J. Pharmacol, 76, 413–21.
Barbaccia, M.L., Gandolfi, O., Chuang, D.M., and Costa, E. (1983). Modulation of neuronal uptake by a putative endogenous ligand of imipramine recognition sites. Proc. Nat. Acad. Sci, 80, 5134–8.
Berridge, M.J., Downes, C.P., and Hanley, M.R. (1982). Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem. J., 206, 587–95.
Blier, P., and De Montigny, C. (1985). Short-term lithium administration enhances seroto-nergic neurotransmission: Electrophysiological evidence in the rat CNS. Europ. J. Pharmacol, 113, 69–77.
Bradley, P.B., Engel, G., Feniuk, W., Fozard, J.R., Humphrey, P.P.A., Middlemiss, D.N., Mylecharane, E.J., Richardson, B.P., and Saxena, P.R. (1986). Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuro-pharmacology, 25, 563–76.
Checkley, S.A., Meldrum, B.S., and McWilliam, J.R. (1984). Mechanism of action of ECT.
Neuroendocrine studies. In Lerer, B., Weiner, R.D., and Belmaker, R.H. (eds.), ECT: Basic Mechanisms (Biological Psychiatry: New Prospects, 1). Libbey, London, 101–6.
Costain, D.W., Cowen, P.J., Gelder, M.G., and Grahame-Smith, D.G. (1982). Electrocon-vulsive therapy in the brain: evidence for increased dopamine mediated responses. Lancet, ii, 400–4.
Cowen, P.J., Fraser, S., Grahame-Smith, D.G., Green, A.R., and Stamford, C. (1983). The effect of chronic antidepressant administration on β-adrenoceptor function of the rat pineal. Br. J. Pharmac, 78, 89–96.
Cowen, P.J., Geaney, D.P., Schachter, M., Green, A.R., and Elliott, J.M. (1986). Des-methylimipramine treatment in normal subjects: effects on neuroendocrine responses to L-tryptophan and platelet 5HT related receptors. Archives of General Psychiatry, 43, 61–7.
Cowen, P.J., Green, A.R., Grahame-Smith, D.G., and Braddock, L.E. (1985). Plasma melatonin during desmethylimipramine treatment. Evidence for changes in noradrenergic transmission. J. Clin. Pharmac, 19, 799–805.
De Montigny, C, and Blier, P. (1984). Effects of antidepressant treatments in 5HT neurotransmission: electrophysiological and clinical studies. In Usdin,E., Asberg, M., Bertilsson, L., and Sjoqvist, F. (eds.), Frontiers in Biochemical and Pharmacological Research in Depression. Raven, New York, 223–39.
De Montigny, C, and Blier, P. (1985). Electrophysiological aspects of serotonin neuro-pharmacology: implications for antidepressant treatments. In Green, A.R. (ed.), Neuro-pharmacology of Serotonin. Oxford University Press, Oxford, 181–217.
Fink, M. (1979). Convulsive Therapy: Theory and Practice. Raven, New York.
Glue, P.W., Cowen, P.J., Nutt, D.J., Kolakowska, T., and Grahame-Smith, D.G. (1986). The effects of lithium on 5-HT mediated neuroendocrine responses and platelet 5-HT receptors. Psychopharmacology, 90, 398–402.
Godfrey, P.P., Grahame-Smith, D.G., Gray, J.A., and McClue, S.J. (1987). GABAB receptor mediated inhibition of 5-HT stimulated phosphatidylinositol turnover in mouse cerebral cortex. Br. J. Pharmacol, 90, 253.
Goodwin, G.M., De Souza, R.J., Wood, A.J., and Green, A.R. (1986a). Lithium decreases 5-HT1A and 5-HT2 receptor, and α2-adrenoceptor mediated function in mice. Psycho-pharmacology, 90, 482–7.
Goodwin, G.M., De Souza, R.J., Wood, A.J., and Green, A.R. (1986b). The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism. Psychopharmacology, 90, 488–93.
Goodwin, G.M., De Souza, R.J., and Green, A.R. (1985). Presynaptic serotonin receptor mediated response in mice attenuated by antidepressant drugs and electroconvulsive shock. Nature, 317, 531–3.
Grahame-Smith, D.G., and Green, A.R. (1974). The role of 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br. J. Pharmacol, 52, 19–26.
Grahame-Smith, D.G., Green, A.R., and Costain, D.W. (1978). Mechanism of the antidepressant action of electroconvulsive therapy. Lancet, i, 254–6.
Gray, J.A., and Green, A.R. (1986a). Increased GABAB receptor function in mouse frontal cortex after repeated administration of antidepressant drugs or electroconvulsive shocks. Br. J. Pharmacol, 92, 357–62.
Gray, J.A., and Green, A.R. (1986b). Evidence for increased GABAB receptor function in mouse frontal cortex following antidepressant administration. Br. J. Pharmacol, 89, 799.
Green, A.R. (1986a). Changes in GAB A biochemistry and seizure threshold. Ann. NY Acad. Sci., 462, 105–19.
Green, A.R. (1986b). Electroconvulsive therapy: a GABA-ergic mechanism? In Lloyd, K.G., Bartholini, G., and Morselli, P. (eds.) GABA and Mood Disorders. Raven, New York, 57–60.
Green, A.R., and Goodwin, G.M. (1986). Antidepressants and monoamines: actions and interactions. In Deakin, J.F.W. (ed.), The Biology of Depression. Gaskell, London, 175–89.
Green, A.R., Heal, D.J., and Goodwin, G.M. (1986). The effects of electro convulsive therapy in antidepressant drugs on monoamine receptors in rodent brain–similarities and differences. CIBA Foundation Symposium 123, ‘Antidepressants and Receptor Function’. Wiley, Chichester, 246–69.
Green, A.R., and Nutt, D.J. (1983). Antidepressants. In Grahame-Smith, D.G., and Cowen, P.J. (eds.), Psychopharmacology 1, Part 1. Preclinical Psychopharmacology. Excerpta Medica, Amsterdam, 1–37.
Green, A.R., and Nutt, D.J. (1985). Antidepressants. In Grahame-Smith, D.G., and Cowen, P.J. (eds.), Psychopharmacology 2, Part 1. Preclinical Psychopharmacology. Excerpta Medica, Amsterdam, 1–34.
Heal, D.J., Philpot, J., O’Shaughnessy, K.H., and Davis, C.L. (1986). The influence of central noradrenergic function on 5-HT2-mediated head-twitch responses in mice: possible implications for the actions of antidepressant drugs. Psychopharmacology, 89, 414–20.
Lerer, B., Weiner, R.D., and Belmaker, R.H. (eds.) (1984). ECT: Basic Mechanisms. (Biological Psychiatry: New Prospects), 1, Libbey, London.
Lloyd, K.G., Thuvet, F., and Pile, A. (1985). Up-regulation of γ-aminobutyric acid (GABA)B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J. Pharmac. Exp. Ther., 235, 191–9.
Oswald, I., Brezinova, V., and Dunleavy, D.L.F. (1972). On the slowness of action of tri-cyclic antidepressant drugs. Br. J. Psychiat., 120, 673–7.
Porter, R., Boch, G., and Clark, S. (1986). CIBA Foundation Symposium 123: Antidepressants and Receptor Function. Wiley, London.
Raisman, R., Briley, M.S., and Langer, S.Z. (1979). Specific tricyclic antidepressant binding sites in rat brain. Nature, 281, 148–9.
Rehavi, M., Paul, S.M., Skolnick, R., and Goodwin, F. (1980). Demonstration of specific high affinity binding sites for [3H]-imipramine in human brain. Life Sci., 76, 2273–9.
Shopsin, B., Friedman, E., and Gershon, S. (1976). Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch. Gen. Psychiatry, 33, 811–19.
Shopsin, B., Gershon, M., Goldstein, M., Friedman, E., and Wilks, S. (1975). Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol. Commun., 1, 239–49.
Sugrue, M.F. (1983). Chronic antidepressant therapy and associated changed in central monoaminergic functioning. Pharmac. Ther., 21, 1–33.
Swerdlow, M.R., Lee, D., Koob, G.F., and Vaccarino, F.J. (1985). The effects of chronic dietary lithium on behavioural indices of dopamine; denervation supersensitivity in the rat. J. Pharmacol Expt. Therap., 235, 325–9.
Trieser, S.L., Cascio, C.S., O’Donohue, T.L., Thoa, N.B., Jackobowitz, D.M., and Kellar, K.J. (1981). Lithium increases serotonin release and decreases serotonin receptors in hippocampus. Science, 213, 1529–31.
Van Praag, H.M., Flentge, F., Korf, J., Dois, L.C.W., and Schut, T. (1973). A pilot study of the predictive value of the probenicid test in application of 5-hydroxytryptophan as an antidepressent. Psychopharmacologia. (Berl.), 33, 141–51.
Editor information
Editors and Affiliations
Copyright information
© 1988 The Editors and the Contributors
About this chapter
Cite this chapter
Grahame-Smith, D.G. (1988). Neuropharmacological Adaptive Effects in the Actions of Antidepressant Drugs, ECT and Lithium. In: Briley, M., Fillion, G. (eds) New Concepts in Depression. Palgrave, London. https://doi.org/10.1007/978-1-349-09506-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-349-09506-3_1
Publisher Name: Palgrave, London
Print ISBN: 978-1-349-09508-7
Online ISBN: 978-1-349-09506-3
eBook Packages: MedicineMedicine (R0)